- Home
- NRO vs TLSI Comparison
NRO vs TLSI Comparison
Compare NRO & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- TLSI
- Stock Information
- Founded
- NRO 2003
- TLSI 2010
- Country
- NRO United States
- TLSI United States
- Employees
- NRO N/A
- TLSI N/A
- Industry
- NRO Finance/Investors Services
- TLSI Medical Specialities
- Sector
- NRO Finance
- TLSI Health Care
- Exchange
- NRO Nasdaq
- TLSI Nasdaq
- Market Cap
- NRO 189.8M
- TLSI 166.8M
- IPO Year
- NRO N/A
- TLSI N/A
- Fundamental
- Price
- NRO $4.03
- TLSI $4.73
- Analyst Decision
- NRO
- TLSI Strong Buy
- Analyst Count
- NRO 0
- TLSI 2
- Target Price
- NRO N/A
- TLSI $14.00
- AVG Volume (30 Days)
- NRO 239.4K
- TLSI 69.8K
- Earning Date
- NRO 01-01-0001
- TLSI 08-14-2024
- Dividend Yield
- NRO 11.41%
- TLSI N/A
- EPS Growth
- NRO N/A
- TLSI N/A
- EPS
- NRO N/A
- TLSI N/A
- Revenue
- NRO N/A
- TLSI $24,736,000.00
- Revenue This Year
- NRO N/A
- TLSI $61.24
- Revenue Next Year
- NRO N/A
- TLSI $47.32
- P/E Ratio
- NRO N/A
- TLSI N/A
- Revenue Growth
- NRO N/A
- TLSI 67.75
- 52 Week Low
- NRO $2.51
- TLSI $3.32
- 52 Week High
- NRO $3.45
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- NRO 75.35
- TLSI 36.52
- Support Level
- NRO $3.80
- TLSI $4.80
- Resistance Level
- NRO $4.03
- TLSI $5.32
- Average True Range (ATR)
- NRO 0.05
- TLSI 0.34
- MACD
- NRO 0.00
- TLSI -0.02
- Stochastic Oscillator
- NRO 95.65
- TLSI 3.06
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.